unknown
Stage
1
Investors
About
Arvinas is a biopharmaceutical company that develops therapies based on targeted protein degradation (PROTAC) to degrade disease-causing proteins. The company advances small-molecule drugs for oncology and other diseases through its protein degrader platform.
Explore Arvinas's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.